Schizandrin
CAS 7432-28-2
Schizandrin (CAS 7432-28-2) is a pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 45907.72727272727 nM | 22 | - |
| - | IC50 | 0.7813333333333333 ug.mL-1 | 6 | - |
| - | Potency | 7354.56 nM | 5 | - |
| - | EC50 | 15.8 ug.mL-1 | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Schizandrin used for in pharmaceutical contexts?
Schizandrin (CAS 7432-28-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Schizandrin?
No adverse-event association or SIDER side-effect rows are rendered for Schizandrin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Schizandrin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Schisandrin with EU status "restricted".
What clinical phase is Schizandrin in?
No phase 1-4 clinical development badge is rendered for Schizandrin because the matched compound identifier rows do not contain a max-phase value.